What four stocks does Bill Gates own?
Through the diversified investment portfolio managed by the Bill & Melinda Gates Foundation Trust, as well as his personal holding vehicle Cascade Investment, Bill Gates holds significant equity stakes across multiple blue-chip corporate giants. While portfolio weights fluctuate periodically through rebalancing, prominent long-term core holdings consistently feature Microsoft Corporation, the massive technology enterprise he co-founded; Berkshire Hathaway, the multinational conglomerate led by his longtime friend Warren Buffett; Waste Management, which provides essential environmental and waste collection services; and Canadian National Railway, reflecting a strategic preference for critical transportation and industrial infrastructure assets that generate robust, predictable cash flows over extended multi-decade investment horizons.
Related FAQs
Bill Gates has invested heavily in numerous cutting-edge biotechnology and genomic companies through his private investment vehicles and philanthropic foundation initiatives.
Elon Musk rarely provides direct individual stock recommendations for retail investors, but his public commentary and business ventures frequently spotlight companies aligned with artificial intelligence, sustainable energy, electric vehicles, space ...
Equity analysts and healthcare portfolio managers evaluating high-growth biotechnology stocks frequently highlight innovative firms possessing robust clinical pipelines and strong commercial revenue trajectories.
In clinical oncology, no single medication or therapeutic agent achieves a universal one hundred percent success rate across all types of cancer due to the extreme genetic and biological heterogeneity of tumors.
Bill Gates has not bought Costco as a company, but the Bill & Melinda Gates Foundation has held shares of Costco Wholesale in its investment portfolio for many years.
No, Brookfield Infrastructure Partners L.P. (BIP) does not pay monthly dividends; it operates on a quarterly distribution schedule. These distributions are typically paid in March, June, September, and December.
Boyd Gaming Corporation, a premier nationwide multi-jurisdictional gaming and entertainment company operating dozens of casino resort properties across the United States, generates substantial annual financial revenues.
Pharmaceutical stocks are often considered a solid investment choice for portfolios seeking defensive stability, steady dividend yields, and long-term growth driven by aging global populations and continuous medical innovation.
The Bill & Melinda Gates Foundation entered into an agreement to purchase equity shares in BioNTech on August 30, 2019, just months prior to the company's official public market initial offering and the onset of the global pandemic.
BioNTech SE faces an evolving future centered on leveraging its proprietary mRNA technology platform beyond infectious disease vaccines into breakthrough oncology treatments, personalized cancer immunotherapies, and advanced autoimmune disease therap...
Mark Zuckerberg's personal equity holdings are overwhelmingly concentrated in Meta Platforms, Inc. (ticker: META), the parent company of Facebook, Instagram, and WhatsApp, where he serves as co-founder, chairman, and chief executive officer.
Yes, the Bill & Melinda Gates Foundation made a direct investment in BioNTech by purchasing over 3 million ordinary shares in 2019.
No, BioNTech SE does not pay a regular dividend. While the company issued a special, one-time dividend in 2022 following a period of high revenue, it has not established a recurring dividend program.
Medical science has successfully developed specific immunization tools that protect the human body against viral infections known to cause cellular mutations and subsequent malignancies over time.
BioNTech SE (BNTX) is a clinical-stage biotechnology pioneer globally recognized for its revolutionary messenger RNA (mRNA) technology platform initially deployed for COVID-19 vaccines and now being aggressively expanded into oncology, infectious dis...
Identifying the best biotechnology corporation for investment involves evaluating firms with strong clinical pipelines, FDA-approved commercial product revenues, robust balance sheets, and proven research leadership.
BioNTech outlined an aggressive strategic roadmap focusing on its oncology and infectious disease pipelines, announcing plans to initiate multiple new late-stage Phase 3 clinical trials and approach several major data readouts.